CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Event-free survival (EFS) was significantly increased with enasidenib compared to conventional care regimens (CCR) in this open-label, randomized, phase 3 trial; overall survival (OS) was complicated by early dropout and usage of later AML medications. The older R/R mutant-IDH2 AML group received notable morphologic and hematologic responses from enasidenib as opposed to CCR.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
